Aileron Therapeutics announced positive data from cohort 1 of a Phase 1b clinical trial for LTI-03 in patients with idiopathic pulmonary fibrosis, showing potential to reduce fibrosis and inflammation in the lung.
AI Assistant
REIN THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.